This bill (S 2540) amends New Jersey's pretrial release procedures to clarify that courts may require defendants to undergo mental health or substance abuse treatment as a condition of release. It specifies that courts must consider mental health treatment (under subsection i) alongside other non-monetary conditions - like curfews, employment requirements, or electronic monitoring - to ensure defendants appear in court and do not endanger others. The bill directly affects defendants facing pretrial detention who are deemed eligible for release but pose risks requiring structured supervision. It does not create new referral systems but refines existing release conditions to explicitly include treatment options for mental health/substance abuse issues. The bill is currently pending in the Senate Judiciary Committee.
S 3109 requires New Jersey health insurance carriers to submit annual reports to the Department of Banking and Insurance (DOBI) by March 1st. These reports must detail how carriers apply medical necessity criteria and non-quantitative treatment limitations (NQTLs) to mental health and substance use disorder benefits, comparing them to medical/surgical benefits to ensure parity. Key provisions include analyzing whether processes for mental health coverage are applied no more stringently than for other medical services, covering NQTLs like step therapy, network design, and formulary rules. The bill directly affects all health insurers operating in New Jersey, mandating transparency to verify compliance with federal mental health parity laws. This is a procedural requirement focused on monitoring, not altering coverage.
SR 38 is a Senate Resolution urging the New Jersey Department of Health to increase public awareness about the dangers of xylazine, a non-opioid veterinary tranquilizer misused as a street drug. It directly affects New Jersey residents by calling for educational resources on xylazine's risks, including its link to overdose deaths (as it cannot be reversed by naloxone), skin ulcers, and dangerous combinations with fentanyl or other drugs. The resolution does not create new laws but requests the health department develop public outreach materials. It highlights xylazine's role in the Northeast overdose crisis, noting its use via injection, snorting, or mixing with opioids.
This bill requires all New Jersey general acute care hospitals to ask patients aged 18+ if they have a substance use disorder or are in recovery during healthcare services. Hospitals must create public protocols within 180 days for connecting these patients to treatment or referrals. The law directly affects hospitals and patients with substance use disorders by mandating proactive screening and standardized care pathways. It focuses on integrating substance use disorder support into routine hospital care without specifying treatment types or outcomes.
This bill establishes a new Office of Alcohol and Drug Use Disorders Policy within New Jersey's Executive Branch, independent of the Department of the Treasury but reporting directly to the Governor. The office coordinates all state efforts related to substance use disorder treatment, prevention, and research across departments and counties. Key provisions include requiring an annual statewide Master Plan for services, reviewing county plans, distributing grants to localities, and creating a centralized treatment resource database. The office directly affects state agencies, counties, and treatment providers by centralizing coordination and funding recommendations for substance use disorder services.
New Jersey's S 3105 establishes a statewide tele-psychiatry program within the Department of Human Services (DHS) to provide remote mental health and substance abuse crisis care. The program allows licensed providers ("consulting providers") at one location ("consultant site") to deliver real-time video consultations to patients at hospitals or facilities ("referring sites") experiencing acute mental health crises. DHS must contract with a partner organization to implement the program statewide within three years, monitor its effectiveness through annual reports, and facilitate access for rural and critical access hospitals. The bill appropriates $4 million from the General Fund to cover implementation costs, including oversight, site monitoring, and payment rates for tele-psychiatry services. It directly affects hospitals seeking crisis care access, licensed mental health providers, and patients in acute need of psychiatric evaluation.
This bill authorizes licensed outpatient substance use disorder treatment programs in New Jersey to provide housing to patients receiving treatment, specifically for individuals needing both services. Programs must offer housing through a separate contract requiring patients to acknowledge repayment of housing subsidies, and must inform patients that housing and treatment are independent services not contingent on each other. The bill maintains existing criminal penalties for programs accepting payment for patient referrals while allowing treatment programs to own, lease, or manage housing units under state zoning and safety regulations.
This bill requires New Jersey hospitals to offer mental health evaluations to patients treated for drug overdoses before discharge. It mandates that all health insurance plans (including individual, group, hospital service, and medical service contracts) cover these evaluations at the same level as other medical treatments. The policy directly affects overdose patients receiving care at licensed acute care hospitals and insurers providing coverage in New Jersey. It applies to all relevant insurance contracts issued or renewed after the bill's effective date.
This bill increases state funding by $1.5 million for the Center for Great Expectations in Somerset, raising its FY2024 appropriation from $500,000 to $2.0 million. The Center provides safe housing and support services to over 1,000 individuals annually, including homeless or economically marginalized people, pregnant or parenting individuals, and those with mental health or substance use challenges. The additional funds will directly support three key programs: the state's only residential program for adolescents with mental health disorders, an adult residential program for pregnant women, and outpatient mental health/substance abuse services. The bill amends the state's annual budget to adjust the funding line for this specific program.
This bill (S 2144) updates licensing rules for residential substance use disorder treatment facilities in New Jersey. It requires applicants to submit independent financial audits (paid by the applicant) and undergo criminal background checks for all owners or major stakeholders (5%+ ownership), with licensure denied for financial misconduct or convictions involving fraud/dishonesty. The Department of Health must also conduct unannounced facility inspections. These changes directly affect facilities seeking or holding licenses and their owners, aiming to ensure financial accountability and safety through stricter vetting.
